JORGE CASTILLO to Adenine
This is a "connection" page, showing publications JORGE CASTILLO has written about Adenine.
Connection Strength
5.115
-
How to Sequence Therapies in Waldenstr?m Macroglobulinemia. Curr Treat Options Oncol. 2021 08 23; 22(10):92.
Score: 0.722
-
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2021 02 20; 39(6):565-575.
Score: 0.677
-
Zanubrutinib for the treatment of Bing-Neel syndrome. Br J Haematol. 2025 Apr; 206(4):1136-1140.
Score: 0.230
-
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr?m macroglobulinemia. Blood Adv. 2024 04 09; 8(7):1639-1650.
Score: 0.217
-
Bruton tyrosine kinase inhibitors in the management of Waldenstr?m macroglobulinemia. Am J Hematol. 2023 02; 98(2):338-347.
Score: 0.198
-
Natural history of Waldenstr?m macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 2022 05 01; 107(5):1163-1171.
Score: 0.189
-
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022 02; 36(2):532-539.
Score: 0.181
-
Plasmablastic lymphoma transformation in a patient with Waldenstr?m macroglobulinemia treated with ibrutinib. Br J Haematol. 2021 11; 195(3):466-468.
Score: 0.180
-
Partial response or better at six?months is prognostic of superior progression-free survival in Waldenstr?m macroglobulinaemia patients treated with ibrutinib. Br J Haematol. 2021 02; 192(3):542-550.
Score: 0.171
-
Genomic evolution of ibrutinib-resistant clones in Waldenstr?m macroglobulinaemia. Br J Haematol. 2020 06; 189(6):1165-1170.
Score: 0.163
-
What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 11; 33(11):2555-2562.
Score: 0.159
-
How we manage Bing-Neel syndrome. Br J Haematol. 2019 11; 187(3):277-285.
Score: 0.157
-
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstr?m macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019 11; 187(3):356-363.
Score: 0.156
-
Ibrutinib and Rituximab in Waldenstr?m's Macroglobulinemia. N Engl J Med. 2018 11 15; 379(20):1973-4.
Score: 0.149
-
Ibrutinib Monotherapy in Symptomatic, Treatment-Na?ve Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761.
Score: 0.146
-
Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstr?m macroglobulinemia. Haematologica. 2018 10; 103(10):e466-e468.
Score: 0.144
-
Ibrutinib withdrawal symptoms in patients with Waldenstr?m macroglobulinemia. Haematologica. 2018 07; 103(7):e307-e310.
Score: 0.142
-
Ibrutinib discontinuation in Waldenstr?m macroglobulinemia: Etiologies, outcomes, and IgM rebound. Am J Hematol. 2018 08; 93(4):511-517.
Score: 0.141
-
Atrial fibrillation associated with ibrutinib in Waldenstr?m macroglobulinemia. Am J Hematol. 2016 06; 91(6):E312-3.
Score: 0.125
-
Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leuk Lymphoma. 2016 11; 57(11):2699-701.
Score: 0.124
-
Biology, prognosis, and therapy of Waldenstr?m Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95.
Score: 0.114
-
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012 Mar; 21(3):355-61.
Score: 0.093
-
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024 Dec; 21(12):867-887.
Score: 0.056
-
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr?m macroglobulinemia: the ASPEN study. Blood. 2020 10 29; 136(18):2038-2050.
Score: 0.043
-
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020 05 21; 135(21):1912-1915.
Score: 0.041
-
CXCR4 mutations affect presentation and outcomes in patients with Waldenstr?m macroglobulinemia: A systematic review. Expert Rev Hematol. 2019 10; 12(10):873-881.
Score: 0.039
-
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 01 24; 133(4):299-305.
Score: 0.037
-
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenstr?m macroglobulinaemia on ibrutinib. Br J Haematol. 2019 05; 185(4):788-790.
Score: 0.037
-
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstr?m macroglobulinaemia. Br J Haematol. 2019 01; 184(2):242-245.
Score: 0.037
-
Genomics, Signaling, and Treatment of Waldenstr?m Macroglobulinemia. J Clin Oncol. 2017 Mar 20; 35(9):994-1001.
Score: 0.033
-
Ibrutinib for patients with rituximab-refractory Waldenstr?m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb; 18(2):241-250.
Score: 0.033
-
Future therapeutic options for patients with Waldenstr?m macroglobulinemia. Best Pract Res Clin Haematol. 2016 06; 29(2):206-215.
Score: 0.032
-
Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017 10; 179(2):339-341.
Score: 0.032
-
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 06 23; 127(25):3237-52.
Score: 0.031
-
Ibrutinib in previously treated Waldenstr?m's macroglobulinemia. N Engl J Med. 2015 Apr 09; 372(15):1430-40.
Score: 0.029
-
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015 Jul; 170(1):134-8.
Score: 0.029
-
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr?m macroglobulinaemia cells. Br J Haematol. 2015 Mar; 168(5):701-7.
Score: 0.028